Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517855 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers
A Phase 1 study, sponsored by Protalex.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00517855 is a Phase 1 study that has completed, run by Protalex. The registered enrollment target is 20 participants.
The verdict
NCT00517855, a Phase 1 study, has completed, sponsored by Protalex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is the second human clinical study with PRTX-100. It is designed to assess the safety of a single intravenous (IV) dose of PRTX-100, as well as, how the drug is eliminated from the blood after dosing. Additionally, this study provides an opportunity to monitor immune system response to PRTX-100.
Interventions
- BIOLOGICAL PRTX-100 (Staphylococcal protein A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517855
The ClinicalTrials.gov registry entry for NCT00517855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protalex, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRTX-100 (Staphylococcal protein A) is the first listed.
NCT00517855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517855 about?
NCT00517855 is a clinical study titled "Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers". This study is the second human clinical study with PRTX-100. It is designed to assess the safety of a single intravenous (IV) dose of PRTX-100, as well as, how the drug is eliminated from the blood after dosing. Additionally, this study provides an opportunity to monitor immune system response to PR...
What is the current status of trial NCT00517855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-06. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00517855?
The interventions under investigation include: PRTX-100 (Staphylococcal protein A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00517855?
This trial is sponsored by Protalex, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.